^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    MiRXES

    i
    Other names: MiRXES | MiRXES Pte Ltd
    Related tests:
    Evidence

    News

    4ms
    Mirxes, Universiti Kebangsaan Malaysia partner on colorectal cancer detection test (Precision Medicine Online)
    "Mirxes...has agreed to work with Universiti Kebangsaan Malaysia's Medical Molecular Biology Institute (UMBI) to develop a blood-based test for the early detection of colorectal cancer."
    Licensing / partnership
    5ms
    Thermo Fisher Scientific, National University Hospital and Mirxes collaborate to enhance access to advanced genomic testing for early cancer detection in Singapore (PRNewswire)
    "Thermo Fisher Scientific Inc...the National University Hospital, Singapore (NU- H), and Mirxes, a Singapore-headquartered RNA technology company, signed a Memorandum of Understanding (MoU) agreement on Friday, 14 June 2024. The agreement formalizes the commitment to collaborate, develop and clinically validate advanced, next-generation sequencing (NGS) genomic testing solutions and cancer research tailored specifically to address the needs of the Southeast Asian population."
    Licensing / partnership
    1year
    Singapore’s Mirxes inks agreements for cancer early detection tests in China, Indonesia (Genomeweb)
    "Mirxes...this week that it has recently signed two agreements that will help advance the company's commercial push into China and Indonesia. Earlier this month Mirxes inked a memorandum of understanding with Zhejiang Anji Economic Development District that outlines a path for Mirxes to scale up its cancer early detection blood tests in China."
    Licensing / partnership
    over1year
    Mirxes receives FDA’s Breakthrough Device Designation for GASTROClearTM to advance blood-based cancer early detection (Mirxes Press Release)
    "Mirxes Corporation USA, the wholly owned subsidiary of Mirxes Pte Ltd...announced today that its flagship product GASTROClearTM, a PCR-based in vitro diagnostic test for early detection of gastric (stomach) cancer, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)."
    FDA event
    |
    GASTROClear Test
    over1year
    MiRxes gets $50M in Series D funding, applies to Hong Kong Limited stock exchange (Genomeweb)
    "MiRxes said Wednesday that it has completed a Series D funding round totaling $50 million, which will help accelerate the Singapore-based firm's development of cancer early detection blood tests and other preventive healthcare solutions."
    Financing
    |
    GASTROClear Test
    almost2years
    MiRxes, PT Elion to develop cancer tests for Indonesian population (Genomeweb)
    "Singaporean biotechnology firm MiRxes said on Tuesday that it has reached an agreement with PT Elion Medika Indonesia to develop blood-based tests for the early detection of multiple cancers for the Indonesian market...As part of the arrangement, PT Elion will validate MiRxes' microRNA-based tests for stomach and lung cancer in an Indonesian cohort. The two companies have also established a joint project for creating a multi-cancer blood test based on miRNA and DNA methylation biomarkers found in Indonesian cancer patients."
    Licensing / partnership
    over2years
    MirXes, Singapore Healthcare organizations partner to develop multi-cancer early detection test (Genomeweb)
    "MirXes...said on Thursday it has signed a memorandum of understanding with several Singapore universities and hospitals to launch a study of circulating microRNA and DNA methylation biomarkers for multi-cancer early detection...Under Project CADENCE (cancer detected early can be cured), the partners plan to discover and validate methylation biomarkers to develop a blood-based test for up to nine cancer types, including lung, breast, colorectal, liver, and pancreatic cancer."
    Licensing / partnership